A detailed history of Israel Englander (Millennium Management LLC) transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 27,889 shares of TCRX stock, worth $158,688. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,889
Previous 392,115 92.89%
Holding current value
$158,688
Previous $3.11 Million 94.76%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$5.85 - $9.51 $2.13 Million - $3.46 Million
-364,226 Reduced 92.89%
27,889 $163,000
Q1 2024

May 15, 2024

BUY
$4.89 - $8.3 $1.43 Million - $2.43 Million
293,033 Added 295.75%
392,115 $3.11 Million
Q4 2023

Feb 14, 2024

BUY
$2.66 - $6.76 $263,558 - $669,794
99,082 New
99,082 $577,000
Q4 2022

Feb 14, 2023

BUY
$1.49 - $3.33 $28,673 - $64,082
19,244 New
19,244 $31,000

Others Institutions Holding TCRX

About TScan Therapeutics, Inc.


  • Ticker TCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,929,800
  • Market Cap $108M
  • Description
  • TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...
More about TCRX
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.